Compass Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMPX research report →
Companywww.compasstherapeutics.com
Compass Therapeutics, Inc. , a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
- CEO
- Thomas J. Schuetz
- IPO
- 2021
- Employees
- 35
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $260.67M
- P/E
- -5.16
- P/S
- 0.00
- P/B
- 1.89
- EV/EBITDA
- -2.97
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.75%
- ROIC
- -38.30%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-66,489,000 · -34.66%
- EPS
- $-0.42 · -16.67%
- Op Income
- $-72,839,000
- FCF YoY
- -9.51%
Performance & Tape
- 52W High
- $6.88
- 52W Low
- $1.61
- 50D MA
- $4.19
- 200D MA
- $4.53
- Beta
- 0.67
- Avg Volume
- 7.20M
Get TickerSpark's AI analysis on CMPX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 29, 26 | Lerner Neil | buy | 15,000 |
| Apr 29, 26 | Anderman Jonathan | buy | 25,000 |
| Apr 29, 26 | Anderman Jonathan | other | 25,000 |
| Apr 29, 26 | Lerner Neil | other | 15,000 |
| Feb 8, 26 | Schuetz Thomas J. | other | 36,687 |
| Jan 9, 26 | Schuetz Thomas J. | other | 46,777 |
| Jan 2, 26 | Shin Barry | other | 670,000 |
| Jan 2, 26 | Shin Barry | other | 125,000 |
| Jan 2, 26 | Sirard Cynthia | other | 1,000,000 |
| Jan 2, 26 | Schuetz Thomas J. | other | 250,000 |
Our CMPX Coverage
We haven't published any research on CMPX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMPX Report →